472 related articles for article (PubMed ID: 28385453)
1. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
[TBL] [Abstract][Full Text] [Related]
2. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
3. A Focused Review on the Effects of Preoperative 5α-Reductase Inhibitors Treatment in Patients Undergoing Holmium Laser Enucleation of the Prostate: What Do We Know So Far?
Dimopoulos P; Christopoulos P; Kampantais S
J Endourol; 2018 Feb; 32(2):79-83. PubMed ID: 29161905
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial.
Milonas D; Auskalnis S; Skulcius G; Gudinaviciene I; Jievaltas M; Joniau S
World J Urol; 2017 May; 35(5):721-728. PubMed ID: 27644229
[TBL] [Abstract][Full Text] [Related]
5. 5α-Reductase Inhibitors Could Prevent the Clinical and Pathological Progression of Prostate Cancer: A Meta-analysis.
Yang Y; Hu H; Zhang H; Liu Z; Zhao F; Yang J; Liang G
Urol J; 2021 Apr; 18(3):247-251. PubMed ID: 33840084
[TBL] [Abstract][Full Text] [Related]
6. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
7. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
Fowke JH; Howard L; Andriole GL; Freedland SJ
Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
[TBL] [Abstract][Full Text] [Related]
8. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
[TBL] [Abstract][Full Text] [Related]
9. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
Iwata T; Schultz D; Hicks J; Hubbard GK; Mutton LN; Lotan TL; Bethel C; Lotz MT; Yegnasubramanian S; Nelson WG; Dang CV; Xu M; Anele U; Koh CM; Bieberich CJ; De Marzo AM
PLoS One; 2010 Feb; 5(2):e9427. PubMed ID: 20195545
[TBL] [Abstract][Full Text] [Related]
10. The clinical applications of five-alpha reductase inhibitors.
Loughlin KR
Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
[TBL] [Abstract][Full Text] [Related]
11. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice.
Banach-Petrosky W; Ouyang X; Gao H; Nader K; Ji Y; Suh N; DiPaola RS; Abate-Shen C
Clin Cancer Res; 2006 Oct; 12(19):5895-901. PubMed ID: 17020998
[TBL] [Abstract][Full Text] [Related]
13. Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.
Papachristodoulou A; Heidegger I; Virk RK; Di Bernardo M; Kim JY; Laplaca C; Picech F; Schäfer G; De Castro GJ; Hibshoosh H; Loda M; Klocker H; Rubin MA; Zheng T; Benson MC; McKiernan JM; Dutta A; Abate-Shen C
Eur Urol; 2024 Apr; 85(4):361-372. PubMed ID: 37659962
[TBL] [Abstract][Full Text] [Related]
14. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
15. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
16. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis.
Kim MJ; Bhatia-Gaur R; Banach-Petrosky WA; Desai N; Wang Y; Hayward SW; Cunha GR; Cardiff RD; Shen MM; Abate-Shen C
Cancer Res; 2002 Jun; 62(11):2999-3004. PubMed ID: 12036903
[TBL] [Abstract][Full Text] [Related]
17. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
[TBL] [Abstract][Full Text] [Related]
18. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
Kang MJ; Choi JY; Sim WY; Lew BL
J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
[No Abstract] [Full Text] [Related]
19. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
Murtola TJ; Kujala PM; Tammela TL
Prostate; 2013 Jun; 73(9):923-31. PubMed ID: 23334943
[TBL] [Abstract][Full Text] [Related]
20. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
